about
Protective effect of Chuquiraga spinosa extract on N-methyl-nitrosourea (NMU) induced prostate cancer in ratsSymptomatic diagnosis of prostate cancer in primary care: a structured review.Identification of potential complementary serum biomarkers to differentiate prostate cancer from benign prostatic hyperplasia using gel- and lectin-based proteomics analyses.Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.Risk of prostate cancer associated with benign prostate disease: a primary care case-control study.Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment.A prospective, observational grouped analysis to evaluate the effect of triptorelin on lower urinary tract symptoms in patients with advanced prostate cancer.Association of Alcohol Consumption with Markers of Prostate Health and Reproductive Hormone Profiles: A Multi-Center Study of 4,535 Men in ChinaDiabetes treatment and progression of benign prostatic hyperplasia in community-dwelling black and white men.Oxidative stress measured by thioredoxin reductase level as potential biomarker for prostate cancer.The Influence of Androgen Deprivation Therapy on Prostate Size and Voiding Symptoms in Prostate Cancer Patients in Korea.Clinical and histopathological characteristics of patients with prostate cancer in the BioBank Japan project.Relationship of oestrogen receptor alpha gene polymorphisms with risk for benign prostatic hyperplasia and prostate cancer in Chinese men.The link between benign prostatic hyperplasia and prostate cancer.Hypermethylation of MCAM gene is associated with advanced tumor stage in prostate cancer.Testosterone Replacement Therapy on the Natural History of Prostate Disease.Triptorelin for the relief of lower urinary tract symptoms in men with advanced prostate cancer: results of a prospective, observational, grouped-analysis study.Effect of triptorelin on lower urinary tract symptoms in Australian prostate cancer patients.Triptorelin in the Relief of Lower Urinary Tract Symptoms in Advanced Prostate Cancer Patients: The RESULT Study.Curcumin inhibits prostate cancer metastasis in vivo by targeting the inflammatory cytokines CXCL1 and -2.Prostate cancer outcomes for men who present with symptoms at diagnosis.Risk behaviours and benign prostatic hyperplasia.Clinical features of prostate cancer before diagnosis: a population-based, case-control study.Joint effects of inflammation and androgen metabolism on prostate cancer severity.Prostate carcinoma risk subsequent to diagnosis of benign prostatic hyperplasia: a population-based cohort study in Sweden.The expressions of AMACR and iNOS in prostate adenocarcinomas.Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.Plasma organochlorine levels and prostate cancer risk.The prevalence and correlates of urinary tract symptoms in Norwegian men: the HUNT study.Can androgen-deprivation therapy obviate the need of channel transurethral resection of the prostate in advanced prostate cancer with urinary retention? A prospective study.Medical history, body size, and cigarette smoking in relation to fatal prostate cancer.Disorder, Promiscuous Interactions, and Stochasticity Regulate State Switching in the Unstable Prostate.Prostate stem cell antigen (PSCA) mRNA expression in peripheral blood in patients with benign prostatic hyperplasia and/or prostate cancer.Family history of cancer and the risk of prostate cancer and benign prostatic hyperplasia
P2860
Q33739126-C5EFF071-287C-4669-9B8C-35B8EEED271DQ34247769-0FBE434B-CBFD-4CF5-B3AD-B3C085B9C425Q34319541-76F2A0F1-4C2C-43C2-A090-DD8A7A5D34DAQ34637448-5F28CE1C-7FD2-4379-A282-862FF9C0F3CAQ35511834-2D0BFF1E-FBC6-4302-AF80-68EBA6800849Q35645345-22401074-131A-4C61-A221-9568566D1335Q35797395-571DB7D9-6707-47E1-995D-5F5AA881117EQ35838637-C68B88AA-45D5-454A-9C3C-CAFAA7D480F0Q35927069-3753B208-01F4-47EB-9B55-64C28A4B91EAQ36250649-44191337-B0E8-4667-A7B9-EDFA7A4693C4Q37554004-8D5A7F81-DDF9-4B96-B8ED-ED91FDBC6A6EQ37700218-78CCA10A-9529-450B-987B-E21BC7C5DC78Q37737283-C3F14090-E1C0-474E-95CB-0987F7EABD2DQ38061029-9953B0E8-2277-4890-85A7-69E43BF63EDFQ38502677-B3D5E026-7C03-4A2D-A188-259D20825971Q38528388-888B54B9-508A-4590-9C18-21C64CDD8FD2Q38658856-9CB455AA-D1ED-4A47-A171-73935C3936C6Q38928284-E38118C0-E5B6-468E-AFFE-6BFB2223E3BCQ39193963-09A13861-9809-4CB5-BB54-8331A9280C03Q39264604-BFDEF8F1-C981-42A5-AC8B-D4110E604D86Q39526823-ADF8EA40-FB41-4827-B1FD-3E3BD928DC37Q39686642-97A866F9-C0A6-4ABE-AC61-8BDAE5290699Q39770035-1E13E68B-7D2E-4202-8E94-A839710F8160Q41931088-7CEE56FD-1987-43D7-A4E6-64CF880335C7Q42610545-4EB0DE4C-7D4D-470D-BC6B-09FEE3449A76Q42933208-58EAB9A8-7375-4A28-B625-5E9D4BCBFF2AQ45342413-7A0EDE15-087E-45F2-9991-9395FC1C143CQ45975768-5DA4070C-14B9-4D82-B5AB-12934E6EFAC8Q46552897-95C9E9B0-E446-4D86-B665-9D6B0CD7D995Q47136887-DC3DFACB-82E8-4EA4-A897-E720051296AEQ47172526-5464C0AA-624B-4DC2-8621-3E491BA15FC5Q53106730-3CAA9D7D-E7AF-4E44-92A9-BC1B415EA2FFQ53610140-D53D510D-A984-4D1A-89AE-24BC55F5226DQ57560034-0CACDC10-4A06-4322-BA7E-A8A93501981F
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Benign prostatic hyperplasia and prostate cancer.
@ast
Benign prostatic hyperplasia and prostate cancer.
@en
Benign prostatic hyperplasia and prostate cancer.
@nl
type
label
Benign prostatic hyperplasia and prostate cancer.
@ast
Benign prostatic hyperplasia and prostate cancer.
@en
Benign prostatic hyperplasia and prostate cancer.
@nl
prefLabel
Benign prostatic hyperplasia and prostate cancer.
@ast
Benign prostatic hyperplasia and prostate cancer.
@en
Benign prostatic hyperplasia and prostate cancer.
@nl
P1476
Benign prostatic hyperplasia and prostate cancer.
@en
P2093
P304
P356
10.1093/OXFORDJOURNALS.EPIREV.A000782
P577
2001-01-01T00:00:00Z